

Ivan Ferraz-Amaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7275142/publications.pdf>

Version: 2024-02-01

120
papers

7,612
citations

101543

36
h-index

54911

84
g-index

132
all docs

132
docs citations

132
times ranked

10978
citing authors

#	ARTICLE	IF	CITATIONS
1	QRISK3 relation to carotid plaque is higher than that of score in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 1408-1416.	1.9	8
2	Disease activity in patients with rheumatoid arthritis increases serum levels of apolipoprotein C-III. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
3	SCORE2 <i>versus</i> SCORE in patients with systemic lupus erythematosus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210923.	2.7	3
4	Alpha-Klotho protein in systemic lupus erythematosus.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
5	The angiotensin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis is disrupted in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 99.	3.5	7
6	Apolipoprotein C-III in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2022, 24, 104.	3.5	3
7	Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00500.	2.5	4
8	Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152037.	3.4	6
9	Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	4
10	Management of Cardiovascular Disease Risk in Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3487.	2.4	4
11	Combined use of QRISK3 and SCORE as predictors of carotid plaques in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 2801-2807.	1.9	14
12	Differences in Capacity of High-Density Lipoprotein Cholesterol Efflux Between Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1590-1596.	3.4	12
13	Higher Prevalence and Degree of Insulin Resistance in Patients With Rheumatoid Arthritis Than in Patients With Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021, 48, 339-347.	2.0	10
14	The validity of salivary gland scintigraphy in Sjögren's syndrome diagnosis: comparison of visual and excretion fraction analyses. <i>Clinical Rheumatology</i> , 2021, 40, 1923-1931.	2.2	8
15	Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity. <i>Rheumatology</i> , 2021, 60, 2296-2306.	1.9	10
16	Beta-cell function is disrupted in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 3826-3833.	1.9	8
17	Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110337.	2.7	5
18	HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 62.	3.5	10

#	ARTICLE	IF	CITATIONS
19	Comment on: Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity: reply. <i>Rheumatology</i> , 2021, 60, e268-e269.	1.9	0
20	Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis: multicentre study of 263 Caucasian patients. <i>Rheumatology</i> , 2021, 61, 299-308.	1.9	13
21	Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 395-403.	3.4	14
22	Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk. <i>Journal of Clinical Medicine</i> , 2021, 10, 1671.	2.4	8
23	HLA-B*08 Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti-Carbamylated Protein Antibody-Positive/Cyclic Citrullinated Peptide-Negative Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 963-969.	5.6	12
24	Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk. <i>Arthritis Research and Therapy</i> , 2021, 23, 162.	3.5	13
25	Insulin Resistance Is Not Increased in Inflammatory Bowel Disease Patients but Is Related to Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 3062.	2.4	6
26	QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 4102.	2.4	1
27	Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project. <i>Journal of Clinical Medicine</i> , 2021, 10, 382.	2.4	11
28	Moderate and High Disease Activity Predicts the Development of Carotid Plaque in Rheumatoid Arthritis Patients without Classic Cardiovascular Risk Factors: Six Years Follow-Up Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4975.	2.4	9
29	Amylin serum levels are upregulated in patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
30	SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. <i>Diagnostics</i> , 2021, 11, 2363.	2.6	3
31	Apolipoprotein C3 and beta-cell dysfunction are linked in patients with systemic lupus erythematosus.. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
32	Eficacia y seguridad de la terapia combinada con fármacos modificadores de la enfermedad sintomáticos en la artritis reumatoide: revisión sistemática de la literatura. <i>Reumatología Clínica</i> , 2020, 16, 324-332.	0.5	4
33	Unmet needs in the management of cardiovascular risk in inflammatory joint diseases. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 23-36.	3.0	16
34	Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. <i>Rheumatology</i> , 2020, 59, 3906-3916.	1.9	64
35	Effect of cardiovascular disease on chronic inflammatory joint disease: reverse causality?. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 855-858.	3.0	0
36	Impact of disease activity on physical activity in psoriatic arthritis patients.. <i>Arthritis Care and Research</i> , 2020, 73, 1834-1844.	3.4	5

#	ARTICLE	IF	CITATIONS
37	The Number of Traditional Cardiovascular Risk Factors Is Independently Correlated with Disease Activity in Patients with Psoriatic Arthritis. <i>Medicina (Lithuania)</i> , 2020, 56, 415.	2.0	7
38	Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2097590.	2.7	16
39	The Performance of Vascular Age in the Assessment of Cardiovascular Risk of Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 4065.	2.4	2
40	Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis. <i>Rheumatology</i> , 2020, 59, 2847-2856.	1.9	30
41	Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 1344-1353.	2.0	11
42	HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients. <i>Clinical Rheumatology</i> , 2020, 39, 1871-1880.	2.2	10
43	Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models. <i>Arthritis Research and Therapy</i> , 2020, 22, 90.	3.5	11
44	Carotid plaques as predictors of cardiovascular events in patients with Rheumatoid Arthritis. Results from a 5-year-prospective follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1333-1338.	3.4	31
45	Reclassification into very-high cardiovascular risk after carotid ultrasound in patients with axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 724-731.	0.8	5
46	Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 18-24.	0.8	3
47	Effect of IL-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type-9 and Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients. <i>Hormone and Metabolic Research</i> , 2019, 51, 200-209.	1.5	27
48	IL-6: linking chronic inflammation and vascular calcification. <i>Nature Reviews Rheumatology</i> , 2019, 15, 457-459.	8.0	42
49	Adipokines: Linking metabolic syndrome, the immune system, and arthritic diseases. <i>Biochemical Pharmacology</i> , 2019, 165, 196-206.	4.4	119
50	AB0730â€¦RECLASSIFICATION INTO VERY HIGH CARDIOVASCULAR RISK AFTER CAROTID ULTRASOUND IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		2
51	Cardiovascular disease in the QUEST-RA study, 10â€‰%years later. <i>Arthritis Research and Therapy</i> , 2019, 21, 242.	3.5	3
52	Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019, 46, 483-491.	2.0	13
53	Identification of a 3â€‰â€²Untranslated Genetic Variant of <i>RARB</i> Associated With Carotid Intimaâ€‰Media Thickness in Rheumatoid Arthritis: A Genomeâ€‰Wide Association Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 351-360.	5.6	26
54	Relationship Between Insulin Sensitivity and Î²-Cell Secretion in Nondiabetic Subjects with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 229-236.	2.0	10

#	ARTICLE	IF	CITATIONS
55	Sex and Cardiovascular Involvement in Inflammatory Joint Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 278-292.	6.5	13
56	Implication of CXCL5 (epithelial neutrophil-activating peptide 78) in the development of insulin resistance in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 373-379.	0.8	2
57	Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA project. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 731-739.	0.8	6
58	Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 22-27.	3.4	123
59	Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2018, 85, 317-322.	1.6	29
60	Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 48-54.	0.9	194
61	Cardiovascular risk stratification in axial spondyloarthritis: carotid ultrasound is more sensitive than coronary artery calcification score to detect high-cardiovascular risk axial spondyloarthritis patients. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 73-80.	0.8	16
62	Amylin in the insulin resistance of patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 421-427.	0.8	2
63	Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis. <i>Scientific Reports</i> , 2017, 7, 40303.	3.3	12
64	European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO). <i>Autoimmunity Reviews</i> , 2017, 16, 548-554.	5.8	44
65	HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis. <i>Arthritis Research and Therapy</i> , 2017, 19, 113.	3.5	39
66	Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. <i>Rheumatology</i> , 2017, 56, 1102-1110.	1.9	100
67	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. <i>Scientific Reports</i> , 2017, 7, 5088.	3.3	44
68	Coronary Artery Calcification and Rheumatoid Arthritis: Lack of Relationship to Risk Alleles for Coronary Artery Disease in the General Population. <i>Arthritis and Rheumatology</i> , 2017, 69, 529-541.	5.6	12
69	Terapias biológicas y manifestaciones neurológicas. ¿Qué sabemos?. <i>Reumatología Clínica</i> , 2017, 13, 102-106.	0.5	3
70	Incretins in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 229.	3.5	12
71	Insulin resistance in systemic lupus erythematosus patients: contributing factors and relationship with subclinical atherosclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 885-892.	0.8	14
72	Undifferentiated connective tissue disease: predictors of evolution into definite disease. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 739-745.	0.8	13

#	ARTICLE	IF	CITATIONS
73	Cardiovascular risk factor assessment: still an unmet need in chronic inflammatory diseases. <i>Heart</i> , 2016, 102, 1937-1939.	2.9	9
74	Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. <i>Autoimmunity Reviews</i> , 2016, 15, 1013-1030.	5.8	107
75	Cardiovascular disease in inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 851-869.	3.3	95
76	Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis. <i>Scientific Reports</i> , 2016, 6, 31979.	3.3	23
77	Serum cathepsin S and cystatin C: relationship to subclinical carotid atherosclerosis in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 230-5.	0.8	7
78	Protective Role of the Interleukin 33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Rheumatoid Arthritis Patients. <i>PLoS ONE</i> , 2015, 10, e0143153.	2.5	21
79	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
80	Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study. <i>Rheumatology International</i> , 2015, 35, 1825-1836.	3.0	8
81	Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 618-626.	3.4	94
82	Actualizaci3n 2014 del Documento de Consenso de la Sociedad Espa3ola de Reumatolog3a sobre el uso de terapias biol3gicas en la artritis reumatoide. <i>Reumatolog3a Cl3nica</i> , 2015, 11, 279-294.	0.5	89
83	Osteoprotegerin Concentrations Relate Independently to Established Cardiovascular Disease in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 39-45.	2.0	26
84	Relationship of abdominal adiposity and body composition with endothelial dysfunction in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 516-23.	0.8	7
85	Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2014, 21, 182-201.	1.9	15
86	Retinol-binding Protein 4 in Rheumatoid Arthritis-related Insulin Resistance and β -cell Function. <i>Journal of Rheumatology</i> , 2014, 41, 658-665.	2.0	12
87	Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: Scientific evidence and expert opinion. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 1-8.	3.4	66
88	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014, 506, 376-381.	27.8	1,974
89	Influence of disease activity on the physical activity of rheumatoid arthritis patients. <i>Rheumatology</i> , 2014, 53, 722-731.	1.9	73
90	Rheumatoid arthritis and metabolic syndrome. <i>Nature Reviews Rheumatology</i> , 2014, 10, 691-696.	8.0	154

#	ARTICLE	IF	CITATIONS
91	Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1281-1283.	0.9	73
92	Fine Mapping Seronegative and Seropositive Rheumatoid Arthritis to Shared and Distinct HLA Alleles by Adjusting for the Effects of Heterogeneity. <i>American Journal of Human Genetics</i> , 2014, 94, 522-532.	6.2	156
93	Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 722-727.	0.9	190
94	Impaired beta cell function is present in nondiabetic rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2013, 15, R17.	3.5	20
95	Metabolic Syndrome in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2013, 2013, 1-11.	3.0	77
96	Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1764-1770.	0.9	123
97	Cholesteryl Ester Transfer Protein in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1040-1047.	2.0	18
98	Angiotensin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 761-6.	0.8	18
99	Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 796-798.	0.9	34
100	Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy. <i>Mediators of Inflammation</i> , 2012, 2012, 1-8.	3.0	50
101	Validated methods for assessment of subclinical atherosclerosis in rheumatology. <i>Nature Reviews Rheumatology</i> , 2012, 8, 224-234.	8.0	118
102	Obesity impairs efficacy of anti-TNF therapy in patients with RA. <i>Nature Reviews Rheumatology</i> , 2012, 8, 641-642.	8.0	20
103	NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. <i>Atherosclerosis</i> , 2012, 224, 426-429.	0.8	72
104	TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 850-5.	0.8	32
105	Carotid Intima Media Thickness in Rheumatoid Arthritis as Compared to Control Subjects: A Meta-Analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 389-397.	3.4	120
106	Thematic stream: co-morbidity: BPP7. Effect of Anti Tnf-Alpha Therapies on Insulin Resistance, Body Composition and Adipokines in Rheumatoid Arthritis Patients. <i>Rheumatology</i> , 2011, 50, ii4-ii5.	1.9	0
107	Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF therapy. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 153-159.	3.8	125
108	A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, R71.	3.5	71

#	ARTICLE	IF	CITATIONS
109	Carotid Intima-Media Thickness Predicts the Development of Cardiovascular Events in Patients with Rheumatoid Arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 38, 366-371.	3.4	211
110	Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice. <i>Reumatología Clínica</i> , 2009, 5, 252-258.	0.5	13
111	Endothelial Dysfunction, Carotid Intima-Media Thickness, and Accelerated Atherosclerosis in Rheumatoid Arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 67-70.	3.4	96
112	Clinical and Molecular Genetic Spectrum of Congenital Deficiency of the Leptin Receptor. <i>New England Journal of Medicine</i> , 2007, 356, 237-247.	27.0	610
113	HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 125-132.	6.7	312
114	Effect of anti-tumor necrosis factor γ therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 55, 150-153.	6.7	86
115	Rheumatoid Arthritis: A Disease Associated with Accelerated Atherogenesis. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 8-17.	3.4	282
116	High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1219-23.	2.0	187
117	Increased Prevalence of Severe Subclinical Atherosclerotic Findings in Long-Term Treated Rheumatoid Arthritis Patients Without Clinically Evident Atherosclerotic Disease. <i>Medicine (United States)</i> , 2003, 82, 407-413.	1.0	207
118	Apolipoprotein C3 and beta-cell dysfunction are linked in patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1
119	Alpha-Klotho protein in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	2
120	Amylin serum levels are upregulated in patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1